Twist通过EMT促使结直肠癌SW480细胞获得干性及化疗抵抗能力的作用及机制研究

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (956 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effect of Twist on epithelial-mesenchymal transition (EMT), cancer stem cell phenotype and chemotherapy resistance of SW480 cells. Methods From January to December 2012, 30 colorectal cancer samples were collected in Renmin Hospital, Wuhan University. And the expression of Twist in colon cancer tissues and adjacent tissues were analyzed; the effect of Twist on SW480 cells EMT phenotype switching was detected through the over expression assay. The role of Twist in SW480 cells mammospheres number, cancer stem cell markers expression and chemotherapy resistance were investigated. Results The expression of Twist in colon cancer tissues was significantly higher than that in adjacent tissues (P < 0.05). Twist could promote EMT phenotype switching, evidenced by the changes in cell morphology, the up-regulation of interstitial-associated N-cadherin expression, and the significant inhibition of epithelial-associated E-cadherin expression (P < 0.05). Twist increased mammospheres number and the expression of cancer stem cell markers SW480 cells, such as Bmi-1, Nanog, CD44 in (P < 0.05). Twist could promote SW480 cells to obtain chemotherapy resistance ability through ABCB1/P-gp pathway. Conclusion Twist could promote SW480 cells EMT phenotype switching, stem cell characteristics and chemotherapy resistance ability obtaining, indicating that Twist could serve as a potential target for chemotherapy resistance of colorectal cancer.

Key words： Colorectal cancer Twist Epithelial-mesenchymal transition Cancer stem cell Chemotherapy resistant

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DENG Junjian1 ZHANG Fan2 BAO Wenting1 XIONG Lin1 LIU Yuanshi1 FAN Li1 XU Ximing1

Cite this article:

DENG Junjian1 ZHANG Fan2 BAO Wenting1 XIONG Lin1 LIU Yuanshi1 FAN Li1 XU Ximing1. Effect and mechanism of twist promoting stem cell ability obtaining and chemotherapy resistance of colorectal cancer SW480 cells by EMT[J]. 中国医药导报, 2019, 16(18): 4-8,24.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I18/4

[1] Christofori G. New signals from the invasive front [J]. Nature，2006，441（7092）：444-450.
[2] Thiery JP，Acloque H，Huang RY，et al. Epithelialmesenchymal transitions in development and disease [J]. Cell，2009， 139（5）：871-890.
[3] Kalluri R， Weinberg RA. The basics of epithelial-mesenchymal transition [J]. J Clin Invest，2009，119（6）：1420-1428.
[4] Wu Y， Zhou BP. Snail：More than EMT [J]. Cell Adh Migr，2010，4（2）：199-203.
[5] Campbell K. Contribution of epithelial-mesenchymal transitions to organogenesis and cancer metastasis [J]. Curr Opin Cell Biol，2018，55：30-35.
[6] Diepenbruck M，Christofori G. Epithelial-mesenchymal transition （EMT） and metastasis：yes，no，maybe? [J]. Curr Opin Cell Biol，2016，43：7-13.
[7] Liu B，Miyake H，Nishikawa M，et al. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder：correlation with intravesical recurrence following transurethral resection [J]. Urol Oncol，2015，33（3）：110.
[8] Sui H，Zhu L，Deng W，et al. Epithelial-mesenchymal transition and drug resistance：role，molecular mechanisms，and therapeutic strategies [J]. Oncol Res Treat，2014，37（10）：584-589.
[9] Huang J，Li H，Ren G. Epithelial-mesenchymal transition and drug resistance in breast cancer （Review）[J]. Int J Oncol，2015，47（3）：840-848.
[10] Dong CY，Liu XY，Wang N，et al. Twist-1，a novel regulator of hematopoietic stem cell self-renewal and myeloid lineage development [J]. Stem Cells，2014，32（12）：3173-3182.
[11] Pirinen E，Soini Y. A survey of zeb1，twist and claudin 1 and 4 expression during placental development and disease [J]. APMIS，2014，122（6）：530-538.
[12] Brenner H，Kloor M，Pox CP. Colorectal cancer [J]. Lancet，2014，383：1490-502.
[13] Siegel R，DeSantis C，Virgo K，et al. Cancer treatment and survivorship statistics [J]. CA Cancer J Clin，2012， 62（4）：220-241.
[14] Center MM，Jemal A，Smith RA，et al. Worldwide variations in colorectal cancer [J]. CA Cancer J Clin，2009，59（6）：366-378.
[15] Roncucci L，Mariani F. Prevention of colorectal cancer：How many tools do we have in our basket? [J]. Eur J Intern Med，2015，26（10）：752-756.
[16] Goodwin Jinesh G，Willis DL，Kamat AM. Bladder cancer stem cells：biological and therapeutic perspectives[J]. Curr Stem Cell Res Ther，2014，9（2）：89-101.
[17] Islam F，Gopalan V，Wahab R，et al. Cancer stem cells in oesophageal squamous cell carcinoma：Identification，prognostic and treatment perspectives [J]. Crit Rev Oncol Hematol，2015，6（1）：9-19.
[18] Friedmann-Morvinski D，Verma IM. Dedifferentiation and reprogramming：origins of cancer stem cells [J]. EMBO Rep，2014，15（3）：244-253.
[19] Mladinich M，Ruan D，Chan CH. Tackling cancer stem cells via inhibition of EMT transcription factors [J]. Stem Cells Int，2016，2016：5285892.
[20] Nuti SV，Mor G，Li PR，et al. TWIST and ovarian cancer stem cells：implications for chemoresistance and metastasis [J]. Oncotarget，2014，5（17）：7260-7271.
[21] Hano M，Tomá?觢ová L，?譒ere?觢 M，et al. Interplay between P-Glycoprotein Expression and Resistance to Endoplasmic Reticulum Stressors [J]. Molecules，2018，23（2）.pii：E337. doi：10.3390/molecules23020337.
[22] Joshi P，Vishwakarma RA，Bharate SB. Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer [J]. Eur J Med Chem，2017，138：273-292.